fbpx
EVENTS|NEWS|CONTACT|DONATE
Read Our Newsletter

News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
PD-1 protein
Oct 28 2020

Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer

Basilea Pharmaceutica has started a study of a drug that inhibits the cancer-driving protein FGFR. It will be studied alone and with the anti-PD-1 drug Tecentriq in gastric cancer patients.

Read Source
, ,

Social Media

   

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Please join with us to fuel the next wave of progress.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.
Please join with us to fuel the next wave of progress. Support our 2024 Fundraising Campaign.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Together, we will defeat stomach cancer.

Together, we will defeat stomach cancer.

MORE INFODONATE
X